Fibromyalgia & Addiction: Why Chronic Pain Increases Substance Use Risk

Fibromyalgia and chronic pain can create a complex interplay with mental health and, unfortunately, increase the risk of self-medication and potential substance leverage disorders. The underlying mechanisms involve how the brain processes pain, coupled with the psychological burden of living with a chronic condition. Understanding this connection is crucial for both patients and clinicians.

The Pain-Addiction Connection in Fibromyalgia

Fibromyalgia involves abnormal pain processing; the brain struggles to regulate pain signals effectively. This isn’t simply a matter of ‘feeling’ pain more intensely, but a fundamental disruption in how pain is perceived and managed. Remarkably, many of the brain pathways involved in fibromyalgia also play a role in addiction, creating what researchers describe as a “fertile breeding ground” for problematic substance use. This overlap isn’t coincidental. Addiction, like chronic pain, involves central sensitization – a heightened responsiveness of the nervous system – and a cycle of seeking relief, even if temporary.

Individuals with fibromyalgia often report experiencing stigma during healthcare consultations, feeling invalidated, discouraged, or judged by clinicians. This can stem from a historical lack of understanding surrounding the condition, with some questioning its legitimacy. However, research confirms that fibromyalgia is a valid diagnosis, and importantly, that individuals with fibromyalgia are at increased risk of developing substance use disorders (SUDs). Approximately 3 to 6% of the U.S. Population suffers from fibromyalgia, with women being disproportionately affected.

Understanding Nociplastic Pain and Self-Medication

Fibromyalgia pain is classified as “nociplastic pain,” a chronic pain arising from altered central nervous system (CNS) function rather than tissue damage or inflammation. This is a critical distinction. Unlike the pain from an injury or arthritis, fibromyalgia pain is often widespread, unrelenting, and doesn’t respond predictably to traditional pain management approaches. When medications provide only partial or inconsistent relief, patients may turn to self-medication strategies, such as alcohol or cannabis, in an attempt to cope. This isn’t necessarily driven by a desire for euphoria, but by a desperate need for pain relief.

Research from Dr. Roland Staud at the University of Florida demonstrates that fibromyalgia patients exhibit increased sensitivity to pain (hyperalgesia), yet their ability to modulate pain input is comparable to healthy controls. This suggests that the pain isn’t necessarily originating from a problem with the body’s initial pain signaling, but rather an amplification of that signal within the central nervous system – a kind of “systems overload.” Unfortunately, unlike a computer, the body can’t simply be turned off and reset.

The Role of Opioids, Cannabis, and Alcohol

Opioid use disorder (OUD) is a frequent co-occurring condition with chronic pain. Patients with fibromyalgia are 50% more likely to use opioids regularly or at high doses compared to those with other pain conditions. However, there’s little convincing evidence that opioids effectively treat fibromyalgia pain, and chronic use may actually increase pain through opioid-induced hyperalgesia. Despite this, opioids can provide transient relief from distress, reinforcing their use through short-term symptom dampening.

Cannabis use is also highly prevalent among individuals with fibromyalgia, with nearly 50% reporting use since diagnosis. Both “medical” and recreational cannabis are increasingly viewed as alternative pain therapeutics. Studies have shown that adults with chronic pain are significantly more likely to have cannabis use disorder (CUD) than those without pain. Pain News Network reports on the growing interest in medical cannabis for fibromyalgia symptoms.

Alcohol misuse also represents a significant risk in chronic pain populations. Data from the U.S. National Inpatient Sample indicates that while alcohol use disorder (AUD)-related hospitalizations have increased across various musculoskeletal conditions, the rate of increase is highest in fibromyalgia patients.

Beyond Pain: The Impact of Co-occurring Conditions

Fibromyalgia often presents with a constellation of symptoms beyond pain, including nonrestorative sleep, debilitating fatigue, and cognitive dysfunction. Depression, anxiety, trauma-related symptoms, and sleep disturbances are common, and each of these independently increases the risk of substance use disorders. The combination of these factors creates a complex clinical picture that requires a holistic approach to treatment.

Evidence-Based Management and Emerging Therapies

First-line treatment for fibromyalgia emphasizes nonpharmacologic strategies, including aerobic exercise, yoga, sleep optimization, cognitive-behavioral therapy, and patient education. FDA-approved pharmacologic options include duloxetine, milnacipran, and pregabalin. Recently, in 2025, the drug Tonmya was approved – the first new fibromyalgia treatment in 15 years – demonstrating significant improvements in chronic pain and other core symptoms by targeting nonrestorative sleep.

Emerging research suggests that GLP-1 receptor agonists, such as Ozempic, may offer hope for future pain relief in fibromyalgia patients. A 2025 preclinical study and a 2026 Mayo Clinic study indicate potential benefits through their effects on central sensitization and neuroinflammation. However, Dr. Staud cautions that further research is needed to fully understand the efficacy and safety of GLP-1 agonists for fibromyalgia. Interestingly, these medications are also being investigated for their potential to treat substance use disorders.

What’s Next: Integrated Care and Screening

Given the strong link between fibromyalgia and substance use disorders, clinicians should routinely screen patients with fibromyalgia for SUDs. Addressing co-occurring mental health conditions – depression, anxiety, PTSD, and trauma – is also critical. A comprehensive, integrated approach to care that addresses both the physical and psychological aspects of fibromyalgia is essential. Future research should focus on developing more effective pain management strategies and identifying novel therapies that can reduce the risk of substance use disorders in this vulnerable population.